Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection

Despite a decrease since 2011-2014, viraemic HCV prevalence among PWID in Germany remains high, and treatment coverage is still insufficient. To achieve the WHO targets, universal health coverage and targeted integrated testing and treatment for PWID are needed. PWID receiving OAT and people in prison should be offered testing and treatment at any contact with the medical system. A nationwide monitoring system will help assess successes and remaining gaps, and track progress towards elimination of HCV among PWID in Germany.

Authors

Institutions

Publication Details

Journal
Harm Reduction Journal
Published
2024-12-20
DOI
https://doi.org/10.1186/s12954-024-01119-2
Citations
3
Primary Topic
HIV, Drug Use, Sexual Risk
Type
article
Field-Weighted Citation Impact
1.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection

Stine Nielsen, Amrei Krings, Willehad Rensmann, Gyde Steffen et al.
3 citations
Harm Reduction Journal
HIV, Drug Use, Sexual Risk
1.16
article

Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection

Stine Nielsen, Amrei Krings, Willehad Rensmann, Gyde Steffen, Ruth Zimmermann, Katrin Wimmer, Simone Bayer, Olaf Ostermann, Andreas Walker, Jörg Timm, Miriam G. Gerlich, Nadine Lübke, Esther Neumeier, Kristin Meyer-Schlinkmann, Carsten Tiemann, Markus Backmund, Dirk Schäffer, Astrid Leicht, Sarah Guttmann, Stefan Wiedemann, Hans-Peter Dorsch, Jörg Ciomber, Martin Kießling, Christiane Stöter
article en
3 citations

Abstract

Despite a decrease since 2011-2014, viraemic HCV prevalence among PWID in Germany remains high, and treatment coverage is still insufficient. To achieve the WHO targets, universal health coverage and targeted integrated testing and treatment for PWID are needed. PWID receiving OAT and people in prison should be offered testing and treatment at any contact with the medical system. A nationwide monitoring system will help assess successes and remaining gaps, and track progress towards elimination of HCV among PWID in Germany.

Harm Reduction JournalVol. 21(1)
Statens Serum Institut (DK), Robert Koch Institute (DE), Federal Centre for Health Education (DE), Düsseldorf University Hospital (DE), AB Vista (Germany) (DE), Laboratory Krone (DE), Praxis für Humangenetik (DE), Orthopädische Praxis (DE), Medizinische Einrichtungen des Bezirks Oberpfalz (DE), Heinrich Heine University Düsseldorf (DE)
Bundesministerium für Gesundheit, Robert Koch Institut, Bundeszentrale für gesundheitliche Aufklärung, Statens Serum Institut
Good health and well-being
Openalex Percentile: Top 19%
HIV, Drug Use, Sexual Risk
1.16
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.